Active-ingredient Dossier
Infliximab
Active-ingredient Dossier for Infliximab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: INFLECTRA
- Brand: REMICADE
- Brand: REMSIMA
- Brand: IXIFI
- Brand: RENFLEXIS
- Brand: JAXIMAB
- Therapeutic area: Immunology
What is
Infliximab Infliximab is a monoclonal antibody.
Australian brands containing
Infliximab — INFLECTRA — REMICADE — REMSIMA — IXIFI — RENFLEXIS — JAXIMAB
Therapeutic areas
Infliximab is registered in immunology, with 6 brands containing this ingredient on the ARTG.
Sponsor landscape
Four sponsors market infliximab in Australia: Pfizer, Janssen-Cilag, Celltrion Healthcare, and Samsung Bioepis AU.
PBS and regulatory activity
Three brands containing infliximab have PBS-listed items. The latest PBS schedule date is 1 May 2026. In the 2023–24 financial year, government expenditure on infliximab was $88,111,661.35 across 98,550 prescriptions. Four brands have PBAC outcomes on record, with the latest dated 1 July 2025. Four brands have AusPARs on record, with the latest dated 20 September 2024.